Evaluation of the @entity1082 mRNA test for the detection of XXXX in Japan.

@entity1 @entity75 @entity14043 @entity854 @entity1082 @entity2784
AIMS: For the screening of @entity854 , @entity1082 ) DNA testing is widely used along with Papanicolaou (Pap) testing. Although the sensitivity of the HPV DNA testing is good, its specificity is relatively low. In the present study, the authors evaluated the use of the Gen-Probe APTIMA HPV Assay for the detection of HPV mRNA and compared it with HPV DNA testing. MATERIALS AND METHODS: Liquid cervical Pap specimens collected from 410 @entity1 were assessed using the APTIMA test, the Qiagen Hybrid Capture 2 HPV DNA ( @entity14043 ) Test, and the AMPLICOR HPV Test. RESULTS: The sensitivity and specificity for the detection of high-risk HPV were 85.6% and 99.2% for the APTIMA test, 94.1% and 98.4% for the @entity14043 test, and 90.2% and 95.7% for the AMPLICOR test, respectively. As the severity of the @entity75 progressed, the positive rate of the three tests indicated a similar increase. The clinical sensitivity and specificity for the detection of @entity2784 ( @entity2784 ) were 91.2% and 84.2% for the APTIMA test, 94.5% and 80.4% for the @entity14043 test, and 87.9% and 78.2% for the AMPLICOR test, respectively. CONCLUSION: The APTIMA is sensitive and specific for the detection of high-risk HPV. In the specimens with @entity2784 , the APTIMA test is more specific than the @entity14043 and the AMPLICOR tests. This indicates that the APTIMA test may improve @entity1 management and reduce the cost of screening.
